Cargando…
No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes
OBJECTIVE: This randomized, four-arm, placebo-controlled, dose-ranging phase 2 trial was conducted to determine whether repeated subcutaneous injections of the altered peptide ligand, NBI-6024, designed to inhibit autoreactive T-cells, improves β-cell function in patients with recently diagnosed typ...
Autores principales: | Walter, Markus, Philotheou, Areti, Bonnici, François, Ziegler, Anette-G., Jimenez, Roland |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768201/ https://www.ncbi.nlm.nih.gov/pubmed/19690081 http://dx.doi.org/10.2337/dc09-0449 |
Ejemplares similares
-
NBI and NBI Combined with Magnifying Colonoscopy
por: Iwatate, Mineo, et al.
Publicado: (2012) -
Comparison of Diagnostic Efficacy Between AFI, NBI, and AFI Combined with NBI for Colonic Cancers: A Meta-Analysis
por: Lv, Xiuhe, et al.
Publicado: (2017) -
Endocytoscopy with NBI has the potential to correctly diagnose diminutive colorectal polyps that are difficult to diagnose using conventional NBI
por: Kataoka, Shinichi, et al.
Publicado: (2020) -
No Effect of the 1α,25-Dihydroxyvitamin D(3) on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes
por: Walter, Markus, et al.
Publicado: (2010) -
de.NBI Cloud federation through ELIXIR AAI
por: Belmann, Peter, et al.
Publicado: (2019)